Preventing biofilm formation and associated occlusion by biomimetic glycocalyxlike polymer in central venous catheters

Journal of Infectious Diseases

Volumn 210, Issue 9, 2014, Pages 1347-1356

  Chauhan, Ashwini ^a   Bernardin, Aude ^b   Mussard, Windy ^b   Kriegel, Irène ^b   Estève, Marc ^b   Ghigo, Jean Marc ^a   Beloin, Christophe ^a   Semetey, Vincent ^b,c  

^a INSTITUT PASTEUR   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT CURIE   (France)

Author keywords

Anti adhesion; Biofilms; Medical devices; Methylcellulose

Indexed keywords

BIOMIMETIC MATERIAL; DIMETICONE; GLYCOCALYXLIKE POLYMER; MACROGOL; METHYLCELLULOSE; NANOFILM; POLYMER; SILICONE; TITANIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BIOFILM; CATHETER INFECTION; CATHETER OCCLUSION; CELL ADHESION; CELL DENSITY; CENTRAL VENOUS CATHETER; COLONY FORMING UNIT; CONTROLLED STUDY; EPIFLUORESCENCE MICROSCOPY; ESCHERICHIA COLI; EUKARYOTIC CELL; GLYCOCALYX; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MATERIAL COATING; NONHUMAN; PERIPHERAL VENOUS CATHETER; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; STAPHYLOCOCCUS AUREUS; SYNTHESIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; CATHETER-RELATED INFECTIONS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; BACTERIAL ADHESION; BIOFILMS; BIOMIMETIC MATERIALS; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERS; GLYCOCALYX; MALE; METHYLCELLULOSE; PSEUDOMONAS INFECTIONS; RATS; STAPHYLOCOCCAL INFECTIONS;

EID: 84907586865     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu249     Document Type: Article

References (41)

1. Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374:159-69.
2. Hartkamp A, van Boxtel AJ, Zonnenberg BA, Witteveen PO. Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems. Neth J Med 2000; 57:215-23.
3. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial bio films. Int J Antimicrob Agents 2010; 35: 322-32.
4. Romling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Int Med 2012; 272:541-61.
5. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clinic proceedings Mayo Clinic 2006; 81:1159-71.
6. Sticca RP, Dewing BD, Harris JD. Totally implantable venous access devices: management in mid- and long-term clinical setting. In: Di Carlo I, Biffi R, eds. Cost Issues, Chap 36. Berlin, Germany: Springer-Verlag, 2012; 257-63.
7. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
8. Ferreira Chacon JM, Hato de Almeida E, de Lourdes Simoes R, et al. Randomized study of minocycline and edetic acid as a locking solution for central line (port-a-cath) in children with cancer. Chemotherapy 2011; 57:285-91.
9. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006; 43:474-84.
10. Chatzinikolaou I, Zipf TF, Hanna H, et al. Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis 2003; 36:116-9.
11. Wolf J, Shenep JL, Clifford V, Curtis N, Flynn PM. Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer 2013; 60:18-25.
12. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997; 127:257-66.
13. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch intern Med 1998; 158:81-7.
14. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999; 340:1-8.
15. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 2004; 22:3163-71.
16. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996; 173:418-24.
17. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo ef ficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol 2001; 22:640-6.
18. US Food and Drug Administration. FDA public health notice: potential hypersensitivity reactions to chlorhexidine-impregnated medical devices. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/Public HealthNotifications/ucm062306.htm. Accessed 15 December 2013.
19. Guleri A, Kumar A, Morgan RJ, HartleyM, Roberts DH. Anaphylaxis to chlorhexidine-coated central venous catheters: a case series and review of the literature. Surg Infect 2012; 13:171-4.
20. Busscher HJ, van der Mei HC, Subbiahdoss G, et al. Biomaterial-associated infection: locating the finish line in the race for the surface. Sci Transl Med 2012; 4:153rv10.
21. Epstein AK, Wong TS, Belisle RA, Boggs EM, Aizenberg J. Liquid-infused structured surfaces with exceptional anti-biofouling performance. Proc Natl Acad Sci U S A 2012; 109:13182-7.
22. Hook AL, Chang CY, Yang J, et al. Combinatorial discovery of polymers resistant to bacterial attachment. Nat Biotechnol 2012; 30:868-75.
23. Smith RS, Zhang Z, Bouchard M, et al. Vascular catheters with a non-leaching poly-sulfobetaine surface modification reduce thrombus formation and microbial attachment. Sci Transl Med 2012; 4:153ra32.
24. Jeon SL, Lee JH, Andrade JD, De Gennes PG. Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. J Colloid Interface Sci 1991; 142:149-58.
25. Rendueles O, Kaplan JB, Ghigo JM. Antibiofilm polysaccharides. Environ Microbiol 2013; 15:334-46.
26. Rendueles O, Travier L, Latour-Lambert P, et al. Screening of Escherichia coli species biodiversity reveals new biofilm-associated antiadhesion polysaccharides. MBio 2011; 2:e00043-11.
27. Valle J, Da Re S, Henry N, et al. Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. Proc Natl Acad Sci U S A 2006; 103:12558-63.
28. Holland NB, Qiu Y, Ruegsegger M, Marchant RE. Biomimetic engineering of non-adhesive glycocalyx-like surfaces using oligosaccharide surfactant polymers. Nature 1998; 392:799-801.
29. Ostuni E, Chapman RG, Holmlin RE, Takayama S, Whitesides GM. A survey of structure-property relationships of surfaces that resist the adsorption of protein. Langmuir 2001; 17:5605-20.
30. MussardW, Kebir N, Kriegel I, EsteveM, Semetey V. Facile and efficient control of bioadhesion on poly(dimethylsiloxane) by using a biomimetic approach. Angew Chem Int Ed Engl 2011; 50:10871-4.
31. Chauhan A, Lebeaux D, Decante B, et al. A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections. PloS One 2012; 7:e37281.
32. Chauhan A, Lebeaux D, Ghigo JM, Beloin C. Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob Agents Chemother 2012; 56:6310-8.
33. Ramphal R, Balloy V, Jyot J, Verma A, Si-Tahar M, Chignard M. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol 2008; 181:586-92.
34. Oberleitner B, Dellinger A, Deforet M, Galtayries A, Castanet AS, Semetey V. A facile and versatile approach to design self-assembled monolayers on glass using thiol-ene chemistry. Chem Commun 2013; 49:1615-7.
35. Adler A, Yaniv I, Steinberg R, et al. Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients. J Hosp Infect2006; 62:358-65.
36. Sotir MJ, Lewis C, Bisher EW, Ray SM, Soucie JM, Blumberg HM. Epidemiology of device-associated infections related to a long-term implantable vascular access device. Infect Control Hosp Epidemiol 1999; 20:187-91.
37. International Organization for Standardization. Biological evaluation of medical devices. Part 5: tests for in vitro cytotoxicity. Vol ISO10993-5. Geneva, Switzerland: International Organization for Standardization, 1999.
38. Raad I, CostertonW, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168:400-7.
39. van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23:2655-60.
40. Crowley AL, Peterson GE, Benjamin DK Jr, et al. Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med 2008; 36:385-90.
41. Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol 2006; 59:212-30.